• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $QCLS

    Q/C Technologies Inc.

    Subscribe to $QCLS
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IPO Year: 2014

    Exchange: NASDAQ

    Recent Analyst Ratings for Q/C Technologies Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Q/C Technologies Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference

      New initiative aimed at developing optical computing technologies to overcome the performance and energy limitations of traditional electronic architectures New York, NY, March 18, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), today announced the launch of a new initiative to design and prototype a proprietary optical processing unit (OPU) aimed at tackling the growing performance and energy constraints in artificial intelligence inference infrastructure. Optical computing overcomes challenges posed by electronic GPUs. Artificial intelligence is dominated by one operation: the matrix multiplication. Photons can be configured to perform matrix m

    3/18/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

    New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C Technologies" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems. Her expertise spans machine learning infrastructure, model evaluation, hardware reliability, and published research contributions including results across image generation, ML interpretability, and reinforcement le

    1/20/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli

    New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage growth. Q/C Technologies welcomes Martin as part of its expanding advisory team alongside James Altucher, further strengthening the Company's depth of expertise across computing, AI, and blockchain technologies. "I'm convinced that the next leap in frontier computing is optical, not purely quantum. Q/C's ‘quantum class' technology approach bridges f

    12/9/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units

    Breakthrough LPUs designed to compute at quantum-class speed using natural light instead of electrical signals to achieve quantum computer speeds Set to outpace GPUs and QPUs (quantum processing units) with higher speed, efficiency, scale and sustainability New York, NY, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced its collaboration with LightSolver, the inventor and owner of the quantum-class laser processing unit (LPU) technology. Through this collaboration, Q/C becomes the first client to adapt LightSolver's proprietary LPU technology for quantum-class applic

    10/30/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives

    Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or the "Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor. Dr. Frankel will help guide the Company's ongoing efforts in quantum-class photonic computing to advance the development and commercialization of Q/C's innovative Laser Processing Unit (LPU). Developed by LightSolver, Q/C's LPU is the world's first light and laser-based computing system designed to solve complex optimization an

    10/16/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. Leadership Updates

    Live Leadership Updates

    View All

    Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

    New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C Technologies" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems. Her expertise spans machine learning infrastructure, model evaluation, hardware reliability, and published research contributions including results across image generation, ML interpretability, and reinforcement le

    1/20/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives

    Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or the "Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor. Dr. Frankel will help guide the Company's ongoing efforts in quantum-class photonic computing to advance the development and commercialization of Q/C's innovative Laser Processing Unit (LPU). Developed by LightSolver, Q/C's LPU is the world's first light and laser-based computing system designed to solve complex optimization an

    10/16/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. SEC Filings

    View All

    SEC Form 10-K filed by Q/C Technologies Inc.

    10-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    4/15/26 5:20:18 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form NT 10-K filed by Q/C Technologies Inc.

    NT 10-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    3/31/26 4:30:23 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    3/13/26 4:30:38 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Q/C Technologies Inc.

    EFFECT - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    2/18/26 12:15:06 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-3 filed by Q/C Technologies Inc.

    S-3 - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    2/11/26 5:17:47 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    1/23/26 5:00:48 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    12/9/25 9:25:02 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B3 filed by Q/C Technologies Inc.

    424B3 - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    12/1/25 5:21:30 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Q/C Technologies Inc.

    EFFECT - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    12/1/25 12:15:11 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Q/C Technologies Inc.

    10-Q - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    11/19/25 5:13:42 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by White Billy Joe

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:10 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Friscia Stephen

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:11 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Voss Chelsea Sierra

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:11 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Bernstein Bruce

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:09 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Glass Mitchell

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:10 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Silverman Joshua

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:09 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Voss Chelsea Sierra was granted 237,500 shares, increasing direct ownership by 9,896% to 239,900 units (SEC Form 4)

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    1/30/26 5:31:25 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Voss Chelsea Sierra claimed ownership of 62,202 shares (SEC Form 3)

    3 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    1/30/26 5:30:24 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Large owner Pharmacyte Biotech, Inc.

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    11/18/25 4:32:29 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director White Billy Joe was granted 22,839 shares, increasing direct ownership by 1,045% to 25,024 units (SEC Form 4)

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    11/17/25 5:30:01 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care